Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05605535 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jan 15, 2026 to Oct 15, 2026 Site details revised at 1 of 14 sitesv10 Show 1 more changeShow less
    • Site details revised at 1 of 14 sites
  2. Primary completion date: Sep 15, 2024 to Jan 15, 2026 Trial status: Recruiting to Active, Not Recruiting · Study sites: 16 to 14 · Completion date: May 15, 2026 to Sep 15, 2027v9 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 16 to 14
    • Completion date: May 15, 2026 to Sep 15, 2027
  3. Site details revised at 2 of 16 sitesv8
  4. Site details revised at 2 of 16 sitesv7
  5. Study sites: 15 to 16v6
Show 4 earlier versionsHide 4 earlier versions
  1. Site details revised at 2 of 15 sitesv5
  2. Eligibility criteria expanded, about 125 words Site details revised at 1 of 15 sitesv4 Show 1 more changeShow less
    • Site details revised at 1 of 15 sites

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 8 to 15 · Start date changed from estimate of Dec 12, 2022 to Feb 7, 2023v3 Show 2 more changesShow less
    • Study sites: 8 to 15
    • Start date changed from estimate of Dec 12, 2022 to Feb 7, 2023
  4. Start date: Nov 15, 2022 to Dec 12, 2022 Site contacts updated at 3 of 8 sitesv2 Show 1 more changeShow less
    • Site contacts updated at 3 of 8 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A clinical study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newly diagnosed advanced ovarian cancer who are planned to receive neoadjuvant treatment followed by interval debulking surgery (IDS) and adjuvant treatment.
Trial Details
NCT Number NCT05605535
Lead Sponsor CanariaBio Inc.
Collaborators: Raptim Research
Conditions Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma, Ovarian Serous Adenocarcinoma
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov